OCGN · Ocugen, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these factors, together with the anticipated continued spending that will be necessary to continue to research, develop, and commercialize the Company's product candidates, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed May 8, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $4.47M | $4.41M | $4.06M | $6.04M | — | $0 | $42.62K | — | $0 | $0 | $0 | $0 | |
| $41.48M | $39.75M | $32.13M | $39.57M | $49.76M | $35.11M | $6.35M | $8.09M | $15.63M | $15.57M | $21.58M | $23.24M | |
| $29.24M | $27.58M | $26.69M | $31.99M | $35.11M | $22.92M | $7.97M | $6.08M | $10.2M | $9.38M | $8.53M | $8.27M | |
| — | — | — | — | $480K | — | — | — | — | — | — | — | |
| $70.72M | $67.33M | $58.81M | $71.57M | $84.87M | $58.03M | $21.33M | $14.16M | $30.11M | $24.95M | $30.31M | $31.82M | |
| -$66.25M | -$62.92M | -$54.76M | -$65.53M | -$84.87M | -$58.03M | -$21.28M | -$14.16M | -$30.11M | -$24.95M | -$30.31M | -$31.82M | |
| — | -1425.7% | -1350.36% | -1085.67% | — | — | -49940.68% | — | — | — | — | — | |
| — | — | — | — | -$84.39M | — | — | — | — | — | — | — | |
| — | $5.19M | — | — | — | $79K | $720.96K | $1.77M | — | — | $60K | $133K | |
| $711K | $922K | — | — | — | — | $1065 | $1214 | — | — | — | — | |
| -$5.42M | -$4.93M | $703K | $2.45M | $3.52M | -$389K | -$537.24K | -$6.08M | $21.47M | -$1.46M | $14.1M | -$205K | |
| — | -$67.85M | -$54.05M | -$63.08M | -$81.35M | -$58.42M | — | — | -$8.64M | -$26.42M | -$16.21M | -$32.02M | |
| — | $0 | $0 | $0 | $0 | -$52K | — | — | — | — | — | — | |
| -$71.67M | -$67.85M | -$54.05M | -$63.08M | -$81.35M | -$58.37M | -$21.82M | -$20.24M | -$8.64M | -$26.41M | -$16.21M | -$32.02M | |
| — | -1537.41% | -1333.02% | -1045.03% | — | — | -51201.2% | — | — | — | — | — | |
| — | — | — | -$63.08M | — | -$58.37M | -$34.37M | -$20.24M | -$8.52M | -$22.5M | -$13.86M | — | |
| -$71.76M | -$67.83M | -$54.03M | -$63.08M | -$81.33M | -$58.37M | -$21.82M | -$20.24M | — | — | — | — | |
| USD/shares | — | — | — | -$0.26 | -$0.38 | -$0.30 | — | — | -$0.23 | -$0.99 | -$0.97 | — |
| USD/shares | — | — | — | -$0.26 | -$0.38 | -$0.30 | — | — | -$0.79 | -$0.99 | -$2.18 | — |
| shares | — | — | — | 244.33M | 214.6M | 195.01M | 112.24M | 13.89M | 36.4M | 22.67M | 14.26M | 13.23M |
| shares | — | — | — | 244.33M | 214.6M | 195.01M | 112.24M | 13.89M | 37.09M | 22.67M | 14.39M | 13.23M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2021: $47.86K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 312 similar-size Biotechnology companies (of 520 listed).
Valuation over time computed as of each quarter's filing date
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$62,916,000 | -$54,757,000 | -$65,531,000 |